The proportion of diabetics may be a modifying factor because the PPARG Pro12Ala G carrier would have a significant protective effect against CKD when the proportion of CKD patients with diabetes was 100%, and no significant difference was observed when the proportion of diabetics decreased [44]. Here, PPARG is linked to chronic kidney disease.